ASHUMGulf news and Dubai stocks, live

Notification from the company CHAE

Lunate S&P UAE UCITS ETF - Share A - ACCUMLATING 60 pages

Document60 pages, text from the file; its scanned pages read by AshumOpen DFM’s file

Page 1

28 /08/ 2025

Mr. Hamed Ahmed Ali

CEO

Dubai Financial Market (DFM)

Dubai, United Arab Emirates

Greetings,

Subject: Notification by Lunate Capital Limited on behalf of Chimera UCITS ICAV

Please be informed that Lunate Capital Limited received the enclosed Condensed Interim Report & Unaudited Financial Statements from Chimera UCITS ICAV for the Period 1st of January 2025 to 30th of June 2025.

Sincerely,

Sherif SalemHead of Public Markets

٢٨ / ٠٨ / ٢٠٢٥

المحترمالسيد / حامد أحمد علي

الرئيس التنفيذي

سوق دبي المالي (DFM)

دبي، دولة الإمارات العربية المتحدة

تحية طيبة وبعد،

الموضوع: اخطار من شركة لونيت كابيتال ليمتد عن شيميرا يوسيتس ايكاف

نود اعلامكم بأن شركة لونيت كابيتال ليمتد استلمت التقرير المرحلي الموجز والقوائم المالية غير المدققة من شيميرا يوسيتس ايكاف للفترة من 1 يناير ٢٠٢٥ إلى ٣٠ يونيو ٢٠٢٥.

وتفضلوا بقبول وافر الاحترام،

شريف سالممدير إدارة الأسواق المالية

مرفق التقرير السنوي و البيانات من شيميرا يوسيتس ايكاف

Attached: Chimera UCITS ICAV Annual Report and Audited Financial Statements

LUNATE CAPITAL LIMITED12 TH FLOOR, ALMARYAH TOWER,ABU DHABI,UNITED ARAB EMIRATESLUNATE.COM

Lunate Capital Limited is duly licensed and regulated by the ADGM Financial Services Regulatory Authority

Page 2

Chimera UCITS ICAVCondensed Interim Report & Unaudited Financial StatementsFor the financial period from 1 January 2025 to 30 June 2025ICAV Registration Number: C188915

Page 3

Chimera UCITS ICAVCondensed Interim Report & Unaudited Financial StatementsFor the financial period from 1 January 2025 to 30 June 2025Contents PageDirectors and Other Information 1Investment Manager’s Report 2Statement of Financial Position 9Statement of Comprehensive Income 12

Statement of Changes in Net Assets Attributable to Holders of Redeemable Participating Shares 15

Statement of Cash Flows 18Notes to the Unaudited Financial Statements 21Schedule of Investments 38Statement of Portfolio Changes 47

Appendix I: Securities Financing Transactions Regulation (“SFTR”) Disclosures 57

Page 4

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 1

Directors and Other InformationDirectors of the ICAVFeargal Dempsey (Irish)1Seif Fikry (Egyptian)2Jason Loveless (British)2Syl O’Byrne (Irish)1Sherif Salem (Egyptian)2Manager

FundRock Management Company S.A.

5, HeienhaffL-1736 SenningerbergGrand Duchy of Luxembourg

Investment Manager and Global Distributor Lunate Capital Limited

Unit 1, Floor 12, Al Maryah Tower, Abu Dhabi Global Market Square, Al Maryah Island

Abu DhabiUnited Arab EmiratesDepositary*Effective from 3 June 2025

The Bank of New York Mellon SA/NV, Dublin Branch The Shipping Office

20-26 Sir John Rogerson's Quay Grand Canal Dock

Dublin 2D02 Y049IrelandUp to 2 June 2025

The Bank of New York Mellon SA/NV, Dublin Branch Riverside II

Sir John Rogerson’s QuayGrand Canal DockDublin 2IrelandRegistered Office of the ICAVArthur Cox BuildingTen Earlsfort TerraceDublin 2D02 T380IrelandSecretaryBradwell LimitedTen Earlsfort TerraceDublin 2D02 T380IrelandIndependent AuditorsDeloitte Ireland LLP

Chartered Accountants and Statutory Auditors 29 Earlsfort Terrace

Dublin 2D02 AY28IrelandIrish Legal AdvisersArthur CoxTen Earlsfort TerraceDublin 2D02 T380Ireland

* Please refer to Note 21 of the financial statements.

1 Independent and Non-executive Director.

2 Non-executive Director.

Administrator, Registrar and Transfer Agent* Effective from 3 June 2025

BNY Mellon Fund Services (Ireland) Designated Activity Company

The Shipping Office

20-26 Sir John Rogerson's Quay Grand Canal Dock

Dublin 2D02 Y049IrelandUp to 2 June 2025

BNY Mellon Fund Services (Ireland) Designated Activity Company

One Dockland CentralGuild Street

International Financial Services Centre Dublin 1

Ireland

Page 5

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025

2Investment Manager’s Report

The Chimera UCITS ICAV Fund ended the first half of 2025 with assets under management of AED 213.8 million. As of the end of June, there are five sub-funds under the Chimera UCITS ICAV Fund, of which one was launched in February 2021, one was launched in August 2023, and the last three were launched in 2024. The sub-funds are the Chimera S&P UAE UCITS ETF (“the First Sub-Fund”), the Chimera S&P Pakistan UCITS ETF (“the Second Sub-Fund”), the Chimera JP Morgan UAE Bond UCITS ETF (“the Third Sub-Fund”), the Chimera S&P Japan UCITS ETF (“the Fourth Sub-Fund”), and Chimera S&P Germany UCITS ETF (“the Fifth Sub-Fund”).

Chimera S&P UAE UCITS ETF (“the First Sub-Fund”)

The Chimera S&P UAE UCITS ETF has two share classes launched on 23 February 2021, an accumulating share class listed on the Dubai Financial Market (DFM) that replicates the S&P UAE BMI Liquid 20/35 Capped Index NTR (Bloomberg Code:

SPUAECAN) and an income share class listed on the Abu Dhabi Securities Exchange (ADX) that replicates the S&P UAE BMI Liquid 20/35 Capped Index (Bloomberg Code: SPUAECAP). The dividends received by the fund’s income share class are intended to be distributed semi-annually when available. As of 30 June 2025, the DFM-listed Share Class A (Bloomberg code:

CHAE) had a NAV of AED 6.480, and the ADX-listed Share Class D (Bloomberg code: UAED) had a NAV of AED 5.587.

For the first half of 2025, the fund's return was 15.1% compared to the S&P UAE BMI Liquid 20/35 Capped Index’s (the “Index”) return of 15.9%. Since inception, the fund’s return has been 76.6% compared to the index’s 85.1%.

In the second quarter of 2025, a dividend of AED 0.1076 was announced for the ADX-listed Share Class D, yielding 1.9% based on the end-of-June NAV. The ex-dividend date was 30 June 2025, and the payment date is set for 21 July 2025.

* The Fund and Index data specified in the graph are calculated since the inception of the Fund

Page 6

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 3

Investment Manager’s Report (continued)

Chimera S&P UAE UCITS ETF (“the First Sub-Fund”) (continued) Tracking Difference & Tracking Error

The Fund's tracking difference in 1H2025 was -84.3 bps, of which 45.6 bps were management fees, resulting in a gross tracking difference of -38.7 bps.

2021 2022 2023 2024 1H2025 ITD

Fund Return*35.1%-4.8%2.0%17.0%15.1%76.6%

Index Return*36.4%-3.9%2.9%18.3%15.9%85.1%

Tracking Diff (bps)-133.1-90.4-97.7-129.3-84.3-851.6

TER (bps)88.671.495.094.345.6419.6

Tracking Diff gross (bps)-44.5-18.9-2.7-35.1-38.7-432.0

Annualized Tracking Error (bps)33.413.413.010.927.419.8

*All returns are in base currency (AED)

As stated under the Investment Policy of the Chimera S&P UAE UCITS ETF Supplement, it is expected, but not guaranteed, that the level of annual Tracking Difference shall not exceed 2% and the level of annualized Tracking Error shall not exceed 1%, in normal market conditions.

Assets Under Management

The Assets Under Management (AUM) of the Chimera S&P UAE UCITS ETF Fund as of 30 June 2025 was AED 159.6 million. The AUM of Share Class D – Distributing (UAED), listed on the Abu Dhabi Securities Exchange (ADX) were AED 156.4 million, while the AUM of Share Class – A – Accumulating (CHAE), listed on the Dubai Financial Market (DFM) were AED 3.2 million as of 30 June 2025.

Both share classes saw no primary activity during the first half of 2025. The ADX-listed share class (UAED) traded AED 624.8 thousand, while the DFM-listed share class (CHAE) traded AED 647.5 thousand in the secondary market during 1H2025.

The S&P UAE BMI Liquid 20/35 Capped Index was rebalanced twice in the first half of 2025. Two additions and two deletions occurred in the first quarter, and two additions and two deletions occurred in the second quarter.

Chimera S&P Pakistan UCITS ETF (“the Second Sub-Fund”)

The Chimera S&P Pakistan UCITS ETF was launched on 17 August 2023. The fund replicates the S&P Pakistan BMI Liquid 35/20 Capped Index (Bloomberg code: SPPKRCAP), which tracks the performance of the 15 biggest and most liquid stocks listed on the Pakistan Stock Exchange. The fund has one share class – Share Class D Income (Bloomberg code: PKSTN) – and dividends received by the fund are intended to be distributed semi-annually when available.

As of 30 June 2025, the fund’s NAV was PKR 692.941 (AED 8.970). For the first half of 2025, the fund's return in PKR was 5.2% versus the S&P Pakistan BMI Liquid 35/20 Capped Index’s (the “Index”) return of 6.5%. Since inception, the fund’s return is 134.1% versus the index’s 130.3% return.

Page 7

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 4

Investment Manager’s Report (continued)Chimera S&P Pakistan UCITS ETF (“the Second Sub-Fund”) (continued)

* The Fund and Index data specified in the graph are calculated since the inception of the Fund

Tracking Difference

The tracking difference for the Fund in 1H2025 was -133.0 bps, of which 48.8 bps is attributed to management fees, resulting in a gross tracking difference of -84.2 bps. One of the primary causes of this variance is that the fund paid a realized CGT of approximately 39.4 bps and 60.0bps in February 2025 and April 2025. Since the index is a price return index, it does not account for dividends. In 1H2025, the annualized tracking error was 111.1 bps.

2023 2024 1H2025 ITD

Fund Return*23.8%79.7%5.2%134.1%

Index Return*19.4%81.1%6.5%130.3%

Tracking Diff (bps)442.0-135.9-133.0378.0

Total Expense Ratio (bps)36.697.948.8184.6

Tracking Diff gross (bps)478.6-38.084.2562.6

Annualized Tracking Error (bps)29.076.0111.181.1

*All returns are in base currency (PKR)

As stated under the Investment Policy of the Chimera S&P Pakistan UCITS ETF Supplement, it is expected, but not guaranteed, that the level of annual Tracking Difference shall not exceed 2% and the level of annualized Tracking Error shall not exceed 1%, in normal market conditions.

Assets Under Management

As of 30 June 2025, the Chimera S&P Pakistan UCITS ETF had Assets Under Management (AUM) of PKR 629.9 million (AED 9.0 million). During the first half of 2025, the ETF witnessed no primary activity. In the secondary market, the ETF traded for AED 417.9 thousand.

The S&P Pakistan BMI Liquid 35/20 Capped Index was rebalanced twice in the first half of 2025. Two additions and two deletions were made in the first quarter, and one addition and one deletion were made in the second quarter.

Page 8

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 5

Investment Manager’s Report (continued)Chimera JP Morgan UAE Bond UCITS ETF (“the Third Sub-Fund”)

The Chimera JP Morgan UAE Bond UCITS ETF was launched on 25 March 2024. The fund aims to replicate the performance of the J.P Morgan MECI UAE Investment Custom Index, which tracks the performance of liquid, USD-denominated investment-grade instruments from the United Arab Emirates (UAE). The fund has one share class – Share Class D Distributing (Bloomberg code: BONDAE) – and interest received by the fund are intended to be distributed semi-annually when available.

The ETF ended the first half of 2025 with an NAV of USD 1.021 (AED 3.751). During the first half of 2025, the fund’s return in USD (the base currency) was 3.7% versus the J.P Morgan MECI UAE Investment Custom Index’s (the “Index”) return of 4.1%.

Since inception, the fund’s return was 5.7% versus Index’s 7.4% return.

* The Fund and Index data specified in the graph are calculated since inception of the Fund

Tracking Difference & Tracking Error

The tracking difference for the Fund in 1H2025 was 41.1 bps, of which 24.6 bps were management fees, resulting in a gross tracking difference of -16.6 bps. The primary cause of this tracking difference is the trading cost. During the first half of 2025, the annualized tracking error was 54.8 bps.

2024 1H2025 ITD

Fund Return*1.9%3.7%5.7%

Index Return*3.1%4.1%7.4%

Tracking Diff (bps)-122.9-41.1-169.7

Total Expense Ratio (bps)38.624.663.0

Tracking Diff gross (bps)-84.3-16.6106.7

Annualized Tracking Error (bps)62.254.859.4

* All returns are in base currency (USD)

Page 9

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 6

Investment Manager’s Report (continued)

Chimera JP Morgan UAE Bond UCITS ETF ("the Third Sub-Fund") (continued)

Tracking Difference & Tracking Error (continued)

As stated under the Investment Policy of the Chimera JP Morgan UAE Bond UCITS ETF Supplement, it is expected, but not guaranteed, that the level of annual Tracking Difference gross of fees shall not exceed 2% and the level of annualized Tracking Error shall not exceed 1%, in normal market conditions.

Assets Under Management

During the first half of 2025 the Chimera JP Morgan UAE Bond UCITS ETF had Assets Under Management (AUM) of USD 5.1 million (AED 18.7 million). During the first half of 2025, the ETF did not witness any primary activity. In the secondary market, the total traded value of the ETF traded for AED was 2.4 million.

There were five monthly rebalancing of the J.P Morgan MECI UAE Investment Custom Index from January to July, resulting in a total of 20 additions and 10 deletions. Given that the ETF follows a sampling strategy, the ETF had 10 additions and 10 deletions during the same period.

Chimera S&P Japan UCITS ETF (“the Fourth Sub-Fund”)

The Chimera S&P Japan UCITS ETF was launched on 28 May 2024. The fund replicates the S&P Japan BMI Liquid 35/20 Capped Index (Bloomberg code: SPJPLCAP), which tracks the performance of the 30 biggest and most liquid stocks listed on the Tokyo Stock Exchange. The fund has one share class – Share Class D Income (Bloomberg code: JPANI) – and dividends received by the fund are intended to be distributed semi-annually when available.

As of 30 June 2025, the fund’s NAV was JPY 162.954 (AED 4.152). For the first half of 2025, the fund's return in JPY was 1.8%, compared to the S&P Japan BMI Liquid 35/20 Capped Index’s (the “Index”) return of 1.6%. Since inception, the fund’s return is 3.8% versus the index’s 3.2% return.

In the second quarter of 2025, a dividend of JPY 0.3467 was announced for the Chimera S&P Japan UCITS ETF, yielding 0.2% based on the end-of-June NAV. The ex-dividend date was 30 June 2025, and the payment date is set for 21 July 2025.

* The Fund and Index data specified in the graph are calculated since the inception of the Fund

Page 10

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 7

Investment Manager’s Report (continued)Chimera S&P Japan UCITS ETF (“the Fourth Sub-Fund”) (continued)Tracking Difference

The Fund's tracking difference in 1H2025 was 21.0 bps, of which 53.0 bps is attributed to management fees, resulting in a gross tracking difference of 74.0 bps. In 1H2025, the annualized tracking error was 49.1 bps.

2024 1H2025 ITD

Fund Return*1.9%1.8%3.8%

Index Return*1.6%1.6%3.2%

Tracking Diff (bps)35.421.058.0

Total Expense Ratio (bps)57.053.0105.0

Tracking Diff gross (bps)92.474.0163.0

Annualized Tracking Error (bps)22.049.136.8

*All returns are in base currency (JPY)

As stated under the Investment Policy of the Chimera S&P Japan UCITS ETF Supplement, it is expected, but not guaranteed, that the annual Tracking Difference (net of fees) will not exceed 2% and the annualized Tracking Error will not exceed 1% in normal market conditions.

Assets Under Management

As of 30 June 2025, the Chimera S&P Japan UCITS ETF had Assets Under Management (AUM) of JPY 570.3 million (AED 14.5 million). During the first half of 2025, the ETF witnessed no primary trading. In the secondary market, it traded for AED 2.6 million.

The S&P Japan BMI Liquid 35/20 Capped Index was rebalanced twice in the first half of 2025. Three additions and three deletions were made in the first quarter, and one addition and one deletion were made in the second quarter.

Chimera S&P Germany UCITS ETF (“the Fifth Sub-Fund”)

The Chimera S&P Germany UCITS ETF was launched on 25 September 2024. The fund replicates the S&P Germany BMI Liquid 35/20 Capped Index (Bloomberg code: SPDELCAP), which tracks the performance of the 30 biggest and most liquid stocks listed on the German Stock Exchange. The fund has one share class – Share Class D Income (Bloomberg code: GRMNY) – and dividends received by the fund are intended to be distributed semi-annually when available.

As of 30 June 2025, the fund’s NAV was EUR 1.104 (AED 4.762). For the first half of 2025, the fund's return in EUR was 18.1%, compared to the S&P Germany BMI Liquid 35/20 Capped Index’s (the “Index”) return of 17.8%. Since inception, the fund’s return is 22.9% versus the index’s 23.0% return.

During the second quarter of 2025, a dividend of EUR 0.0138 was announced for the Chimera S&P Germany UCITS ETF, translating into a dividend yield of 1.3% based on the end-of-June NAV. The ex-dividend date was 30 June 2025, and the payment date is 21 July 2025.

Page 11

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 8

Investment Manager’s Report (continued)Chimera S&P Germany UCITS ETF (“the Fifth Sub-Fund”) (continued)

* The Fund and Index data specified in the graph are calculated since the inception of the Fund Tracking Difference

The Fund's tracking difference in 1H2025 was 30.0 bps, of which 49.0 bps is attributed to management fees, resulting in a gross tracking difference of 79.0 bps. In 1H2025, the annualized tracking error was 27.1 bps.

2024 1H2025 ITD

Fund Return*4.0%18.1%22.9%

Index Return*4.4%17.8%23.0%

Tracking Diff (bps)-37.530.0-14.0

Total Expense Ratio (bps)26.349.074.5

Tracking Diff gross (bps)-11.279.060.5

Annualized Tracking Error (bps)14.427.123.5

*All returns are in base currency (EUR)

As stated under the Investment Policy of the Chimera S&P Germany UCITS ETF Supplement, it is expected, but not guaranteed, that the annual Tracking Difference (net of fees) will not exceed 2% and the annualized Tracking Error will not exceed 1% in normal market conditions.

Assets Under Management

As of 30 June 2025, the Chimera S&P Germany UCITS ETF had Assets Under Management (AUM) of EUR 2.8 million (AED 11.9 million). During the first half of 2025, total primary trading activity was AED 3.7 million, all in redemptions. In the secondary market, the ETF traded for AED 5.5 million.

The S&P Germany BMI Liquid 35/20 Capped Index was rebalanced twice in the first half of 2025. One addition and one deletion occurred in the first quarter, and two additions and two deletions occurred in the second quarter.

Date: 16 July 2025

Page 12

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 9

Statement of Financial PositionChimera S&PUAEUCITS ETFChimera S&PUAEUCITS ETFChimera S&PPakistanUCITS ETFChimera S&PPakistanUCITS ETFAs at30 June2025As at31 December2024As at30 June2025As at31 December2024Notes AED AED PKR PKRAssets

Cash and cash equivalents63,723,2152,883,67021,884,05621,901,444

Financial assets at fair value through profit or loss:

Transferable securities3159,368,831141,162,125672,803,414638,270,579

Total assets163,092,046144,045,795694,687,470660,172,023

Liabilities

Accrued Management fees10(397,826)(353,521)(1,746,335)(1,443,025)

Distributions Payable(3,012,800)(2,293,200)––

Total liabilities(3,410,626)(2,646,721)(1,746,335)(1,443,025)

Net assets attributable to holders of

redeemable participating shares14159,681,420141,399,074692,941,135658,728,998

Number of redeemable participating shares

Class A Accumulating Shares4500,000500,000––

Class D Distributing Shares428,000,00028,000,0001,000,0001,000,000

Net asset value per share attributable to holders of redeemable participating shares

Class A Accumulating Shares146.4805.632––

Class D Distributing Shares145.5874.949692.941658.729

The accompanying notes form an integral part of these financial statements.

Page 13

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 10

Statement of Financial Position (continued)Chimera JPMorgan UAEBondUCITS ETFChimera JPMorgan UAEBondUCITS ETFChimera S&PJapanUCITS ETFChimera S&PJapanUCITS ETFAs at30 June2025As at31 December2024As at30 June2025As at31 December2024Notes USD USD JPY JPYAssets

Cash and cash equivalents64,7876,9025,840,8872,789,390

Financial assets at fair value through profit or loss:

Transferable securities35,049,8595,038,963566,686,305558,730,611

Dividends receivable217142423,74092,619

Interest income receivable58,26255,879––

Total assets5,113,1255,101,886572,950,932561,612,620

Liabilities

Accrued Management fees10(6,705)(7,016)(1,398,519)(1,541,148)

Distributions Payable––(1,213,449)–

Total liabilities(6,705)(7,016)(2,611,968)(1,541,148)

Net assets attributable to holders of

redeemable participating shares145,106,4205,094,870570,338,964560,071,472

Number of redeemable participating shares

Class D Distributing Shares45,000,0005,000,0003,500,0003,500,000

Net asset value per share attributable to holders of redeemable participating shares

Class D Distributing Shares141.0211.019162.954160.020

The accompanying notes form an integral part of these financial statements.

Page 14

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 11

Statement of Financial Position (continued)Chimera S&PGermanyUCITS ETFChimera S&PGermanyUCITS ETFAs at30 June2025As at31 December2024

NotesEUREUR

Assets

Cash and cash equivalents648,10512,922

Financial assets at fair value through profit or loss:

Transferable securities32,754,6903,269,095

Total assets2,802,7953,282,017

Liabilities

Accrued Management fees10(7,166)(8,486)

Distributions Payable(34,500)–

Total liabilities(41,666)(8,486)

Net assets attributable to holders of

redeemable participating shares142,761,1293,273,531

Number of redeemable participating shares

Class D Income Shares42,500,0003,500,000

Net asset value per share attributable to holders of redeemable participating shares

Class D Income Shares141.1040.935

The accompanying notes form an integral part of these financial statements.

Page 15

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 12

Statement of Comprehensive IncomeChimera S&PUAEUCITS ETFChimera S&PUAEUCITS ETFChimera S&PPakistanUCITS ETFChimera S&PPakistanUCITS ETFFinancial Period1 January 2025to 30 June 2025Financial Period1 January 2024to 30 June 2024Financial Period1 January 2025to 30 June 2025Financial Period1 January 2024to 30 June 2024

AED AEDPKRPKR

Income

Dividend income75,902,1385,279,66720,142,18018,439,464

Net gains/(losses) on financial assets at fair

value through profit or loss516,123,022(9,093,077)40,359,30184,084,729

Total investment income/(expense)22,025,160(3,813,410)60,501,481102,524,193

Operating expenses

Management fees8,10(730,014)(614,162)(3,220,387)(2,033,465)

Capital gains taxes––(7,083,057)–

Total operating expenses(730,014)(614,162)(10,303,444)(2,033,465)

Net income/(expense)21,295,146(4,427,572)50,198,037100,490,728

Finance costsDistributions to holders of redeemable

participating shares16(3,012,800)(2,732,800)(15,985,900)–

Total finance costs(3,012,800)(2,732,800)(15,985,900)–

Profit/(loss) for the financial period/year

before tax18,282,346(7,160,372)34,212,137100,490,728

Increase/(decrease) in net assets resultingfrom operations attributable to holders of

redeemable participating shares18,282,346(7,160,372)34,212,137100,490,728

Gains and losses arose solely from continuing investment activities. There were no gains or losses other than those dealt with in the Statement of Comprehensive Income.

The accompanying notes form an integral part of these financial statements.

Page 16

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 13

Statement of Comprehensive Income (continued)Chimera JPMorgan UAEBondUCITS ETFChimera JPMorgan UAEBondUCITS ETFChimera S&PJapanUCITS ETFChimera S&PJapanUCITS ETFFinancial Period1 January 2025to 30 June 2025Financial Periodfrom25 March 2024to 30 June 2024Financial Period1 January 2025to 30 June 2025Financial Periodfrom28 May 2024to 30 June 2024

USD USDJPYJPY

Income

Interest income125,70378,917––

Dividend income71,451–5,331,95424,172

Net gains/(losses) on financial assets at fair

value through profit or loss568,361(65,191)8,824,92316,754,387

Other income2084––

Total investment income195,53513,81014,156,87716,778,559

Operating expenses

Management fees8,10(12,485)(8,152)(2,675,935)(786,320)

Total operating expenses(12,485)(8,152)(2,675,935)(786,320)

Net income183,0505,65811,480,94215,992,239

Finance costsDistributions to holders of redeemable

participating shares16(171,500)–(1,213,450)–

Interest expense–(107)––

Total finance costs(171,500)(107)(1,213,450)–

Profit for the financial period before tax11,5505,55110,267,49215,992,239

Increase in net assets resulting fromoperations attributable to holders of

redeemable participating shares11,5505,55110,267,49215,992,239

Gains and losses arose solely from continuing investment activities. There were no gains or losses other than those dealt with in the Statement of Comprehensive Income.

The accompanying notes form an integral part of these financial statements.

Page 17

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 14

Statement of Comprehensive Income (continued)Chimera S&PGermanyUCITS ETF*Financial Period1 January 2025to 30 June 2025EURIncome

Dividend income755,499

Net gains on financial assets at fair value

through profit or loss5457,850

Total investment income 513,349 Operating expenses

Management fees8,10(13,708)

Other operating expenses (43)

Total operating expenses (13,751) Net income 499,598

Finance costsDistributions to holders of redeemable

participating shares16(34,500)

Total finance costs (34,500)

Profit for the financial period before tax 465,098 Increase in net assets resulting from

operations attributable to holders ofredeemable participating shares 465,098*Please refer to note 20. Comparative information.

Gains and losses arose solely from continuing investment activities. There were no gains or losses other than those dealt with in the Statement of Comprehensive Income.

The accompanying notes form an integral part of these financial statements.

Page 18

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 15

Statement of Changes in Net Assets Attributable to Holders of Redeemable Participating Shares

Chimera S&PUAEUCITS ETFChimera S&PUAEUCITS ETFChimera S&PPakistanUCITS ETFChimera S&PPakistanUCITS ETFFinancial Period1 January 2025to 30 June 2025Financial Period1 January 2024to 30 June 2024Financial Period1 January 2025to 30 June 2025Financial Period1 January 2024to 30 June 2024

AED AEDPKRPKR

Net assets attributable to holders of redeemable participating shares at

beginning of the financial period141,399,074125,749,452658,728,998366,562,034

Increase/(decrease) in net assets resulting from operations attributable to holders of

redeemable participating shares18,282,346(7,160,372)34,212,137100,490,728

Issue of redeemable participating shares – – – – Increase in net assets resulting from share

transactions––––

Net assets attributable to holders ofredeemable participating shares at end of

the financial period159,681,420118,589,080692,941,135467,052,762

The accompanying notes form an integral part of these financial statements.

Page 19

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 16

Statement of Changes in Net Assets Attributable to Holders of Redeemable Participating Shares (continued) Chimera JP

Morgan UAEBondUCITS ETFChimera JPMorgan UAEBondUCITS ETFChimera S&PJapanUCITS ETFChimera S&PJapanUCITS ETFFinancial Period1 January 2025to 30 June 2025Financial Periodfrom25 March 2024to 30 June 2024Financial Period1 January 2025to 30 June 2025Financial Periodfrom28 May 2024to 30 June 2024

USD USDJPYJPY

Net assets attributable to holders of redeemable participating shares at

beginning of the financial period5,094,870–560,071,472–

Increase in net assets resulting from operations attributable to holders of

redeemable participating shares11,5505,55110,267,49215,992,239

Issue of redeemable participating shares–6,500,000–942,000,000

Redemption of redeemable participating

shares–(496,339)–(79,337,500)

Increase in net assets resulting from share

transactions–6,003,661–862,662,500

Net assets attributable to holders of redeemable participating shares at end of

the financial period5,106,4206,009,212570,338,964878,654,739

The accompanying notes form an integral part of these financial statements.

Page 20

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 17

Statement of Changes in Net Assets Attributable to Holders of Redeemable Participating Shares (continued) Chimera S&P

GermanyUCITS ETF*Financial Period1 January 2025to 30 June 2025EUR

Net assets attributable to holders of redeemable participating shares at

beginning of the financial period 3,273,531 Increase in net assets resulting from operations attributable to holders of redeemable participating shares 465,098 Issue of redeemable participating shares – Redemption of redeemable participating shares (977,500)

Decrease in net assets resulting from share transactions (977,500)

Net assets attributable to holders of

redeemable participating shares at end of the financial period 2,761,129

*Please refer to note 20. Comparative information.

The accompanying notes form an integral part of these financial statements.

Page 21

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 18

Statement of Cash FlowsChimera S&PUAEUCITS ETFChimera S&PUAEUCITS ETFChimera S&PPakistanUCITS ETFChimera S&PPakistanUCITS ETFFinancial Period1 January 2025to 30 June 2025Financial Period1 January 2024to 30 June 2024Financial Period1 January 2025to 30 June 2025Financial Period1 January 2024to 30 June 2024

AED AEDPKRPKR

Cash flows from operating activities

Proceeds from sale of investments8,831,0349,395,266164,915,65156,999,909

Purchase of investments(10,914,717)(11,393,308)(166,172,242)(44,088,216)

Interest income received – – – –

Dividend income received5,902,1385,279,66720,142,18018,439,464

Operating expenses paid(685,710)(614,369)(2,917,077)(1,747,973)

Net cash inflow from operating activities3,132,7452,667,25615,968,51229,603,184

Cash flows from financing activities Distributions paid to holders of redeemable

participating shares16(2,293,200)(1,996,400)(15,985,900)–

Net cash outflow from financing activities(2,293,200)(1,996,400)(15,985,900)–

Net increase/(decrease) in cash and cash

equivalents839,545670,856(17,388)29,603,184

Cash and cash equivalents at beginning of

financial period2,883,6702,520,77921,901,4442,747,144

Cash and cash equivalents at end of the

financial period63,723,2153,191,63521,884,05632,350,328

The accompanying notes form an integral part of these financial statements.

Page 22

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 19

Statement of Cash Flows (continued)Chimera JPMorgan UAEBondUCITS ETFChimera JPMorgan UAEBondUCITS ETFChimera S&PJapanUCITS ETFChimera S&PJapanUCITS ETFFinancial Period1 January 2025to 30 June 2025Financial Periodfrom25 March 2024to 30 June 2024Financial Period1 January 2025to 30 June 2025Financial Periodfrom28 May 2024to 30 June 2024

USD USDJPYJPY

Cash flows from operating activities

Proceeds from sale of investments12,119,9671,027,20546,002,94713,292,837

Purchase of investments1(2,056,831)(6,992,299)(45,133,718)(10,042,415)

Interest income received117,6695,139––

Dividend income received1,376–5,000,833–

Operating expenses paid(12,796)84(2,818,564)–

Net cash inflow/(outflow) from operating

activities169,385(5,959,871)3,051,4983,250,422

Cash flows from financing activities Distributions paid to holders of redeemable

participating shares16(171,500)–(1)–

Interest expense paid–(107)––

Amounts received on issue of redeemable

participating shares1–6,500,000––

Amounts paid on redemption of redeemable

participating shares1–(496,339)––

Net cash (outflow)/inflow from financing

activities(171,500)6,003,554(1)–

Net (decrease)/increase in cash and cash

equivalents(2,115)43,6833,051,4973,250,422

Cash and cash equivalents at beginning of

financial period6,902–2,789,390–

Cash and cash equivalents at end of the

financial period64,78743,6835,840,8873,250,422

1 Chimera S&P Japan UCITS ETF engaged in in-kind subscriptions and redemptions of redeemable participating shares during the prior financial period amounting to JPY 942,000,000 and JPY 79,337,500, respectively (refer to Note 4 to the financial statements for further details). All the subscriptions into and redemptions out of the Sub-Fund for the prior financial period were achieved via in-kind contribution and withdrawal of assets of the same amount representing consideration for purchase and sale of investments.

The accompanying notes form an integral part of these financial statements.

Page 23

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 20

Statement of Cash Flows (continued)Chimera S&PGermanyUCITS ETF*Financial Period1 January 2025to 30 June 2025EURCash flows from operating activitiesProceeds from sale of investments1 90,956Purchase of investments1 (96,201)Interest income received –Dividend income received 55,499Operating expenses paid (15,071)

Net cash inflow from operating activities 35,183 Cash flows from financing activities

Amounts received on issue of redeemable participating shares1 –

Net cash inflow from financing activities – Net increase in cash and cash equivalents 35,183 Cash and cash equivalents at beginning of financial period 12,922

Foreign exchange movement arising from aggregation –

Cash and cash equivalents at end of thefinancial period 6 48,105Bank overdraft at end of the financialperiod –*Please refer to note 20. Comparative information.

1 Chimera S&P S&P Germany UCITS ETF engaged in in-kind redemptions of redeemable participating shares during the financial period amounting to EUR 977,500 (refer to Notes 4 of the financial statements for further details). All redemptions out of the Sub- Fund for the financial period, were achieved via in kind withdrawal of assets of the same amount representing consideration for sale of investments.

The accompanying notes form an integral part of these financial statements.

Page 24

Chimera UCITS ICAVCondensed Interim Report & Unaudited Financial StatementsFor the financial period from 1 January 2025 to 30 June 2025Notes to the Unaudited Financial Statements21

1. Organisation

Chimera UCITS ICAV (the “ICAV’’) is an Irish collective asset-management vehicle registered in Ireland pursuant to the Irish Collective Asset-Management Vehicles Act 2015 (the “ICAV Act”) on 21 January 2019 with registration number C188915 and was authorised by the Central Bank of Ireland (the “CBI”) on 18 November 2020 as an Undertaking for Collective Investment in Transferable Securities (“UCITS”) under the provisions of the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, (as amended) (the “UCITS Regulations”) and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2019 (the “Central Bank UCITS Regulations”).

The ICAV is structured as an umbrella fund with segregated liability between Funds (individually a “Sub-Fund” and collectively “Sub-Funds”). The Instrument of Incorporation provides that the ICAV may offer separate classes of shares, each representing interests in a Sub-Fund comprising a distinct portfolio of investments. In addition, each Sub-Fund may be further divided into a number of different classes within the Sub-Fund. With the prior approval of the CBI, the ICAV from time to time may create additional Sub-Funds. The creation of further share classes shall be notified to and prepared and submitted to the CBI in accordance with the CBI requirements.

As at 30 June 2025, the ICAV consisted of five Sub-Funds - Chimera S&P UAE UCITS ETF (the "Sub-Fund"), launched on 23

February 2021; Chimera S&P Pakistan UCITS ETF (the "Sub-Fund”), launched on 17 August 2023; Chimera JP Morgan UAE Bond UCITS ETF (the "Sub-Fund"), launched on 25 March 2024; Chimera S&P Japan UCITS ETF (the "Sub-Fund"), launched on 28 May 2024; and Chimera S&P Germany UCITS ETF (the "Sub-Fund"), launched on 25 September 2024.

The Sub-Funds seek to provide investors with a total return, taking into account capital and income returns, which reflects the returns of equity and bond indices called the S&P UAE BMI Liquid 20/35 Capped Index (the “Index”), the S&P Pakistan BMI Liquid 35/20 Capped Index (the "Index"), J.P. Morgan MECI UAE Investment Grade Custom Index (the "Index") , the S&P Japan BMI Liquid 35/20 Capped Index (the "Index") and the S&P Germany BMI Liquid 35/20 Capped Index (the "Index"), respectively.

The Index for Chimera S&P UAE UCITS ETF is a modified weighted total return index measuring the performance of 30 of the largest constituents of the S&P UAE BMI Index. The S&P UAE BMI Index is a leading benchmark for tracking performance of the UAE equity markets. The Index is comprised of the constituents of the S&P UAE BMI Index that meet the following eligibility requirements: (i) companies must have no more than ten non-trading days over the previous quarter; and (ii) have a three-month average daily value traded volume of at least US$ 500,000 for at least one of the two quarterly periods preceding the rebalancing reference date.

The Index for Chimera S&P UAE UCITS ETF applies a UCITS capping screen of 20/35. This is to allow the Fund, whose policy is to replicate the Index, to invest up to 20% of its net assets in individual securities with the 20% limit being raised up to 35% in the case of a single issuer were justified by exceptional market conditions which may include the dominance of a particular issuer in the relevant market. The Index provider, S&P, has set triggers in place of at 33%/19% respectively to reset levels to ensure UCITS compliance at all times.

The Index of Chimera S&P Pakistan UCITS ETF is a modified weighted total return index measuring the performance of the top 15 Pakistan domiciled companies ranked in the S&P Pakistan BMI Index. The S&P Pakistan BMI Index is a leading benchmark for tracking performance of Pakistani companies. The Index is comprised of the top 15 constituents of the S&P Pakistan BMI Index that meet the following eligibility requirements: (i) companies must have no more than ten non-trading days over the previous quarter; and (ii) have a six-month average daily value traded of at least US$200,000 for at least one of the two quarterly periods preceding the rebalancing reference date.

The Index follows a six-month average daily traded value of >= $200,000. Stocks failing to meet this level will drop out of the Index once this liquidity screen fails to be met for the six-month period preceding the rebalancing reference date.

The Index of Chimera JP Morgan UAE Bond UCITS ETF is a subset of the J.P. Morgan Middle East Composite Index (MECI) (the "Parent Index"). The Index comprises the UAE investment grade USD-denominated corporate, quasi-sovereign and sovereign bond issues. The Parent Index is a leading index tracking the performance of USD-denominated debt in the Middle East. The index constituents must have a minimum face value outstanding of US$500 million, an outstanding maturity between one and two and a half years and bond ratings of BBB- or higher by at least two out of three ratings agencies of Standard & Poor's, Moody's and Fitch.

Page 25

Chimera UCITS ICAVCondensed Interim Report & Unaudited Financial StatementsFor the financial period from 1 January 2025 to 30 June 2025Notes to the Unaudited Financial Statements (continued)22

1. Organisation (continued)

Index rebalancing occurs monthly on the last business day of each month. The Index applies a dual capping methodology, where all issuers are initially capped at 9.0%. The Index is then recalculated until all issuers are below the cap. The issuers above 4.5% are ranked, and the aggregate of these issuers must be below the 38.0% threshold, the highest ranked issuer that breaches the threshold and all remaining issuers in the index are capped at 4.5% after reweighting is applied. These reset triggers of 4.5%/9.0%/38.0% have been set by the Index Provider, JP Morgan, to ensure compliance with the UCITS diversification rules (ie. the 5/10/40 Rule) by creating a buffer below the regulatory limits.

The Index of Chimera S&P Japan UCITS ETF is modified weighted total return index measuring the performance of the top 30

Japan domiciled companies ranked in the S&P Japan BMI Index. The constituents of the S&P Japan BMI Index meet the following eligibility requirements: (i) companies must have no more than ten non-trading days over the previous quarter; and (ii) have a six-month average daily value traded of at least US$1,000,000 for at least one of the two quarterly periods preceding the rebalancing reference date.

The Index applies a UCITS capping screen of 35%/20%. This is to allow the Fund, whose policy is to replicate the Index, to invest up to 20% of its net assets in individual securities with the 20% limit being raised up to 35% in the case of a single issuer where justified by exceptional market conditions which may include the dominance of a particular issuer in the relevant market.

The Index provider, S&P, has set triggers in place at 33%/19% respectively to reset levels to ensure UCITS compliance at all times.

The Index of Chimera S&P Germany UCITS ETF is a modified weighted total return index measuring the performance of the top 30 German domiciled companies ranked in the S&P Germany Index. The constituents of the S&P Germany BMI Index meet the following eligibility requirements: (i) companies must have no more than ten non-trading days over the previous quarter; and (ii) have a six-month average daily value traded of at least US$1,000,000 for at least one of the two quarterly periods preceding the rebalancing reference date.

The Index applies a capping screen of 35%/20%. This will mean that the Sub-Fund, through investing in equity securities, may invest up to 20% of its net assets in a single security with the 20% limit being raised up to 35% in the case of a single issuer where justified by exceptional market conditions such as a material price movement impacting the weighting of that single component within the Index and necessitating a larger exposure. The Index provider, S&P, has set triggers in place at 33%/19% respectively to reset levels to ensure UCITS compliance.

In order to achieve its investment objective, the investment policy of the Sub-Funds are to invest 100% of their net assets in a portfolio of equity and bond securities that consists of the equity and bond securities of each Index. Lunate Capital Limited (the "Investment Manager"), may deviate from the 100% investment where it is, for whatever reason, not possible to buy and hold a particular Index security.

The Sub-Funds attempt to replicate, before fees and expenses, the performance of each Index. The Investment Manager will seek to do this by replicating so far as possible the investments in each Index by holding all of the securities comprising each Index in approximately the same proportion as its weighting in each Index.

The base currency of Chimera S&P UAE UCITS ETF (the “Sub-Fund”), Chimera S&P Pakistan UCITS ETF (the “Sub- Fund"), Chimera JP Morgan UAE Bond UCITS ETF (the "Sub-Fund), Chimera S&P Japan UCITS ETF (the "Sub-Fund") and Chimera S&P Germany UCITS ETF (the "Sub-Fund”) is the United Arab Emirates Dirham (“AED”), Pakistani Rupee ("PKR"), U.S.

Dollar ("USD"), Japanese Yen ("JPY") and Euro ("EUR") respectively. The base currency of the ICAV is AED. The Net Asset Value per Share will be published and settlement and dealing will be affected in the designated currency of each Class.

The shares of the active Sub-Funds are listed and admitted for trading on the following stock exchanges: Class A Accumulating Shares are listed on the Dubai Financial Market while Class D Distributing Shares are listed on Abu Dhabi Securities Exchange.

Page 26

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 Notes to the Unaudited Financial Statements (continued) 23

2. Material Accounting Policies

(a) Basis of preparation

These condensed interim report and unaudited financial statements have been prepared in accordance with IAS 34, "Interim Financial Reporting", the ICAV Act, the UCITS Regulations and the Central Bank UCITS Regulations and should be read in conjunction with the annual report and audited financial statements for the financial year ended 31 December 2024.

Selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the financial position and performance of the Sub-Fund since the last annual report and audited financial statements.

They do not include all the information required for a full set of annual financial statements prepared in accordance with International Financial Reporting Standards ("IFRS").

The condensed interim report and unaudited financial statements have been prepared on a going concern basis which assumes that the ICAV will continue in operational existence for the foreseeable future and have been prepared under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities at fair value through profit or loss.

The preparation of the condensed interim report and unaudited financial statements in conformity with IFRS requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management’s best knowledge of the amount, event or actions, actual results ultimately may differ from those estimates.

The Directors make estimates and assumptions concerning the future of the ICAV. The resulting accounting estimates will, by definition, seldom equal the related actual results. There are no estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities.

International Financial Reporting Standards

New and revised IFRSs applied with no material effect on the condensed financial statements

In the current period, the ICAV has applied a number of amendments to IFRS Accounting Standards and Interpretations issued by the International Accounting Standards Board (IASB) that are effective for an annual period that begins on or after 1 January 2025.

 Amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates relating to Lack of Exchangeability Other than the above, there are no other significant IFRS Accounting Standards and amendments that were effective for the first time for the financial year beginning on or after 1 January 2025.

New and revised IFRSs in issue but not yet effective

The ICAV has not early adopted any new and revised IFRSs that have been issued but are not yet effective.

New and revised IFRSsEffective for annualperiods beginning onor after

Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures regarding the classification and measurement of financial instruments

1 January 2026

Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures regarding purchase power arrangements

1 January 2026

Page 27

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 Notes to the Unaudited Financial Statements (continued) 24

2. Material Accounting Policies (continued)

(a) Basis of preparation (continued)

New and revised IFRSs in issue but not yet effective (continued) New and revised IFRSs (continued)

Effective for annualperiods beginning onor after

Annual improvements to IFRS Accounting Standards - Volume 11 The pronouncement comprises the following amendments:

 IFRS 1: Hedge accounting by a first-time adopter IFRS 7: Gain or loss on derecognition

 IFRS 7: Disclosure of deferred difference between fair value and transaction price

 IFRS 7: Introduction and credit risk disclosures IFRS 9: Lessee derecognition of lease liabilities IFRS 9: Transaction price IFRS 10: Determination of a “de facto agent” IAS 7: Cost method1 January 2026

IFRS 18 Presentation and Disclosures in Financial Statements 1 January 2027 IFRS 19 Subsidiaries without Public Accountability: Disclosures 1 January 2027 Amendments to IFRS 10 Consolidated Financial Statements and IAS 28 Investments in Associates and Joint Ventures (2011)

Effective date deferredindefinitely. Adoptionis still permitted.

The above stated new standards and amendments are not expected to have any significant impact on the condensed financial statements of the ICAV.

There are no other applicable new standards and amendments to published standards or IFRIC interpretations that have been issued that would be expected to have a material impact on the condensed financial statements of the ICAV.

3. Fair Value

IFRS 13 ‘Fair Value Measurement' requires disclosure relating to the fair value hierarchy in which fair value measurements are categorised as assets and liabilities in the Statement of Financial Position.

The disclosures are based on a three-level fair value hierarchy for the inputs used in valuation techniques to measure fair value.

The fair value of financial assets and financial liabilities traded in an active market (such as trading securities) are based on quoted market prices at the close of trading on the reporting date.

A financial instrument is regarded as quoted in an active market if the quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis. These instruments are included within Level 1 of the hierarchy.

The fair value of financial assets and financial liabilities that are not traded in an active market is determined by using valuation techniques. The ICAV uses a variety of methods and makes assumptions that are based on market conditions existing at the reporting date. These instruments are included within Level 2 of the hierarchy. The fair value hierarchy has the following levels:

Quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1).

Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices) (Level 2).

Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs) (Level 3).

Transfers are deemed to occur at the end of the financial period.

Page 28

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 Notes to the Unaudited Financial Statements (continued) 25

3. Fair Value (continued)

There were no transfers between levels during the financial period ended 30 June 2025 and financial year ended 31 December 2024 for the Sub-Funds.

Chimera S&P UAE UCITS ETF

Financial Assets at Fair Value through Profit or Loss As at 30 June 2025

Level 1 Level 2 Level 3 Total

AEDAEDAEDAED

Transferable securities

Equities159,368,831––159,368,831

Total159,368,831––159,368,831

Chimera S&P UAE UCITS ETF

Financial Assets at Fair Value through Profit or Loss As at 31 December 2024

Level 1 Level 2 Level 3 Total

AEDAEDAEDAED

Transferable securities

Equities141,162,125––141,162,125

Total141,162,125––141,162,125

Chimera S&P Pakistan UCITS ETF

Financial Assets at Fair Value through Profit or Loss As at 30 June 2025

Level 1 Level 2 Level 3 Total

PKRPKRPKRPKR

Transferable securities

Equities672,803,414––672,803,414

Total672,803,414––672,803,414

Chimera S&P Pakistan UCITS ETF

Financial Assets at Fair Value through Profit or Loss As at 31 December 2024

Level 1 Level 2 Level 3 Total

PKRPKRPKRPKR

Transferable securities

Equities638,270,579––638,270,579

Total638,270,579––638,270,579

Page 29

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 Notes to the Unaudited Financial Statements (continued) 26

3. Fair Value (continued)

Chimera JP Morgan UAE Bond UCITS ETF

Financial Assets at Fair Value through Profit or Loss As at 30 June 2025

Level 1 Level 2 Level 3 Total

USDUSDUSDUSD

Transferable securities

Corporate Bonds–4,266,524–4,266,524

Government Bonds–714,907–714,907

Mutual Funds68,428––68,428

Total68,4284,981,431–5,049,859

Chimera JP Morgan UAE Bond UCITS ETF

Financial Assets at Fair Value through Profit or Loss As at 31 December 2024

Level 1 Level 2 Level 3 Total

USDUSDUSDUSD

Transferable securities

Corporate Bonds–4,274,698–4,274,698

Government Bonds–699,189–699,189

Mutual Funds65,076––65,076

Total65,0764,973,887–5,038,963

Chimera S&P Japan UCITS ETF

Financial Assets at Fair Value through Profit or Loss As at 30 June 2025

Level 1 Level 2 Level 3 Total

JPYJPYJPYJPY

Transferable securities

Equities566,686,305––566,686,305

Total566,686,305––566,686,305

Chimera S&P Japan UCITS ETF

Financial Assets at Fair Value through Profit or Loss As at 31 December 2024

Level 1 Level 2 Level 3 Total

JPYJPYJPYJPY

Transferable securities

Equities558,730,611––558,730,611

Total558,730,611––558,730,611

Page 30

Chimera UCITS ICAV

Condensed Interim Report & Unaudited Financial Statements For the financial period from 1 January 2025 to 30 June 2025 Notes to the Unaudited Financial Statements (continued) 27

3. Fair Value (continued)

Chimera S&P Germany UCITS ETF

Financial Assets at Fair Value through Profit or Loss As at 30 June 2025

Level 1 Level 2 Level 3 Total

EUREUREUREUR

Transferable securities

Equities2,754,690––2,754,690

Total2,754,690––2,754,690

Chimera S&P Germany UCITS ETF

Financial Assets at Fair Value through Profit or Loss As at 31 December 2024

Level 1 Level 2 Level 3 Total

EUREUREUREUR

Transferable securities

Equities3,269,095––3,269,095

Total3,269,095––3,269,095

Assets and liabilities not carried at fair value but for which fair value is disclosed

The ICAV’s assets and liabilities (by class) not measured at fair value at 30 June 2025 and 31 December 2024 but for which fair value is disclosed within the fair value hierarchy are considered Level 2, except for cash and cash equivalents, which are considered Level 1.

Cash and cash equivalents include cash on hand and demand deposits held with banks and brokers.

4. Share Capital

The issued share capital of the ICAV shall be not less than the currency equivalent of €2 represented by two subscriber shares of no par value and the maximum issued share capital of the ICAV shall not be more than 500 billion shares of no par value. The share capital of the ICAV shall at all times equal the Net Asset Value of the ICAV.

Subscriber shares entitle the holders to attend and vote at all meetings of the ICAV but do not entitle the holders to participate in the dividends or net assets of any Sub-Fund or of the ICAV. The holders of the subscriber shares shall have one vote for each subscriber share held.

Each of the redeemable shares entitles the Shareholder to participate equally on a pro rata basis in the dividends and net assets of a Sub-Fund attributable to the relevant Class in respect of which they are issued, save in the case of dividends declared prior to becoming a Shareholder.

The Directors reserve the right to predesignate any class of shares from time to time, provided that Shareholders in that class shall first have been notified by the ICAV thirty calendar days in advance that the shares will be predesignated and shall have been given the opportunity to have their shares redeemed by the ICAV, except that this requirement shall not apply where the Directors predesignate shares in issue in order to facilitate the creation of an additional class of shares.

Show all 60 pages